China

Population 2018 1 428 million

Estimates of TB burden*, 2018

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>866 (740–1 000)</td>
<td>61 (52–70)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>18 (9.8–28)</td>
<td>1.2 (0.69–2)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>66 (50–85)</td>
<td>4.6 (3.5–6)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>37 (34–41)</td>
<td>2.6 (2.4–2.9)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.4 (1.2–4)</td>
<td>0.17 (0.08–0.28)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 7.1% (5.6–8.7)
- Previously treated cases: 21% (21–21)

TB case notifications, 2018

- Total new and relapse: 795 245
  - % tested with rapid diagnostics at time of diagnosis: 15%
  - % with known HIV status: 60%
  - % pulmonary: 95%
  - % bacteriologically confirmed**: 37%
  - % children aged 0–14 years: 1%
  - % women: 31%
  - % men: 68%
- Total cases notified: 801 532

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 92% (79–110)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 5% (4–6)

TB/HIV care in new and relapse TB patients, 2018

- Number (%)
  - Patients with known HIV status who are HIV-positive: 7 935 (2%)
  - on antiretroviral therapy: 6 915 (87%)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**:
  - New cases: 58%
  - Previously treated cases: 100%

Laboratory-confirmed cases*

- MDR/RR-TB: 14 636, XDR-TB: 430
- Patients started on treatment**
  - MDR/RR-TB: 8 965, XDR-TB:

MDR/RR-TB cases tested for resistance to second-line drugs

Treatment success rate and cohort size

- Success Cohort
  - New and relapse cases registered in 2017: 93% 764 701
  - Previously treated cases, excluding relapse, registered in 2017: 83% 5 077
  - HIV-positive TB cases registered in 2017: 87% 5 308
  - MDR/RR-TB cases started on second-line treatment in 2016: 92% 5 405
  - XDR-TB cases started on second-line treatment in 2016

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

- National TB budget (US$ millions): 719
  - Funding source: 92% domestic, <1% international, 7% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
### Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-10-18 Data: www.who.int/tb/data